Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022074 · ClinicalTrials.gov registry record · NA
Gabapentin For the Control of Hot Flashes in Women With Breast Cancer
A NA study of Breast Cancer and Depression, sponsored by Gary Morrow.
- Completed
- Registry status
- NA
- Development phase
- 18
- Study locations
NCT00022074 is a NA study of Breast Cancer and Depression that has completed, run by Gary Morrow. The trial reports 18 study locations across 14 states.
The verdict
NCT00022074, a NA study of Breast Cancer and Depression, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- NA
- Development phase
- 18
- Study locations
Study Summary
RATIONALE: Gabapentin may be effective for the control of hot flashes. It is not yet known if gabapentin is effective in treating hot flashes. PURPOSE: Randomized clinical trial to study the effectiveness of gabapentin in controlling hot flashes in women who have breast cancer.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- DRUG gabapentin
Study Locations (18)
Arizona
- CCOP - Greater Phoenix - Phoenix
- CCOP - Scottsdale Oncology Program - Scottsdale
New York
- CCOP - North Shore University Hospital - Manhasset
- CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C. - Syracuse
Ohio
- CCOP - Columbus - Columbus
- CCOP - Dayton - Dayton
Washington
- CCOP - Virginia Mason Research Center - Seattle
- CCOP - Northwest - Tacoma
Alabama
- MBCCOP - Gulf Coast - Mobile
Colorado
- CCOP - Colorado Cancer Research Program, Incorporated - Denver
Hawaii
- MBCCOP - Hawaii - Honolulu
Illinois
- CCOP - Central Illinois - Decatur
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-07 |
| Est. Completion | 2005-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022074
The ClinicalTrials.gov registry entry for NCT00022074 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00022074 reports 18 study locations spanning 14 distinct geographic areas - top geographies include Arizona, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT00022074 about?
NCT00022074 is a clinical study titled "Gabapentin For the Control of Hot Flashes in Women With Breast Cancer". RATIONALE: Gabapentin may be effective for the control of hot flashes. It is not yet known if gabapentin is effective in treating hot flashes. PURPOSE: Randomized clinical trial to study the effectiveness of gabapentin in controlling hot flashes in women who have breast cancer.
What is the current status of trial NCT00022074?
This trial is currently completed. It is a NA study. The study started on 2001-07. Estimated completion is 2005-06.
What conditions does trial NCT00022074 study?
This clinical trial studies the following conditions: Breast Cancer, Depression, Hot Flashes, Anxiety Disorder.
What interventions are being tested in trial NCT00022074?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), gabapentin (DRUG).
Who is sponsoring clinical trial NCT00022074?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00022074 being conducted?
This trial has 18 study locations across Alabama, Arizona, Colorado, Hawaii, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.